2020
A phase 1b expansion study of TAS‐102 with oxaliplatin for refractory metastatic colorectal cancer
Cecchini M, Kortmansky JS, Cui C, Wei W, Thumar JR, Uboha NV, Hafez N, Lacy J, Fischbach NA, Sabbath KD, Gomez CM, Sporn JR, Stein S, Hochster HS. A phase 1b expansion study of TAS‐102 with oxaliplatin for refractory metastatic colorectal cancer. Cancer 2020, 127: 1417-1424. PMID: 33351187, PMCID: PMC8085021, DOI: 10.1002/cncr.33379.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsColorectal NeoplasmsDrug Administration ScheduleDrug CombinationsDrug Resistance, NeoplasmFemaleFluorouracilHumansIrinotecanLeucovorinMaleMiddle AgedOrganoplatinum CompoundsOxaliplatinProgression-Free SurvivalPyrrolidinesResponse Evaluation Criteria in Solid TumorsThymineTrifluridineConceptsMetastatic colorectal cancerOverall response rateRefractory metastatic colorectal cancerProgression-free survivalTAS-102Colorectal cancerDay 1Primary endpointOverall survivalDose escalationDay 5Median progression-free survivalPhase 1b studyMedian overall survivalResponse Evaluation CriteriaTreat populationDose expansionPartial responseStandard dosesUnexpected side effectsStudy treatmentTumor shrinkageUnexpected toxicitiesSide effectsNovel antimetabolite
2015
Ontogeny of plasma proteins, albumin and binding of diazepam, cyclosporine, and deltamethrin
Sethi P, White C, Cummings B, Hines R, Muralidhara S, Bruckner J. Ontogeny of plasma proteins, albumin and binding of diazepam, cyclosporine, and deltamethrin. Pediatric Research 2015, 79: 409-415. PMID: 26571224, DOI: 10.1038/pr.2015.237.Peer-Reviewed Original ResearchConceptsTotal proteinBinding of diazepamUnbound diazepamAlbumin levelsStandard dosesPlasma levelsDrugs/chemicalsPediatric databasePlasma bindingAge groupsMaturational changesAdult levelsCyclosporineDiazepamPlasma albuminThree- to fourfoldPlasma samplesFree drugNeonatesPlasma proteinsPyrethroid insecticidesAge bracketDrugsAlbuminRiskPreliminary Safety, Pharmacokinetics, and Efficacy of Regorafenib, Cisplatin, and Pemetrexed in Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancers
Hellmann MD, Sturm I, Trnkova ZJ, Lettieri J, Diefenbach K, Rizvi NA, Gettinger SN. Preliminary Safety, Pharmacokinetics, and Efficacy of Regorafenib, Cisplatin, and Pemetrexed in Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancers. Clinical Lung Cancer 2015, 16: 514-522. PMID: 26003007, PMCID: PMC4750397, DOI: 10.1016/j.cllc.2015.04.003.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsBevacizumabCarcinoma, Non-Small-Cell LungCisplatinContraindicationsDrug InteractionsFemaleHumansLung NeoplasmsMaleMiddle AgedNeoplasm StagingNeovascularization, PathologicPemetrexedPhenylurea CompoundsPyridinesSurvival AnalysisTreatment OutcomeConceptsEfficacy of regorafenibMedian progression-free survivalChemotherapy-naive patientsProgression-free survivalPhase I trialCell lung cancerLung cancerAcceptable tolerabilityPartial responsePotent antiangiogenic activityI trialStandard dosesPK interactionsAdvanced nonsquamous non-small cell lung cancerNonsquamous non-small cell lung cancerTreatment-related grade 3 adverse eventsNon-small cell lung cancerGrade 3 adverse eventsKinase inhibitorsAntiangiogenic activityMinor pharmacokinetic interactionCombination of bevacizumabAdvanced colorectal cancerGastrointestinal stromal tumorsAdverse events
2014
Phase II Study of Bevacizumab, Temozolomide, and Hypofractionated Stereotactic Radiotherapy for Newly Diagnosed Glioblastoma
Omuro A, Beal K, Gutin P, Karimi S, Correa DD, Kaley TJ, DeAngelis LM, Chan TA, Gavrilovic IT, Nolan C, Hormigo A, Lassman AB, Mellinghoff I, Grommes C, Reiner AS, Panageas KS, Baser RE, Tabar V, Pentsova E, Sanchez J, Barradas-Panchal R, Zhang J, Faivre G, Brennan CW, Abrey LE, Huse JT. Phase II Study of Bevacizumab, Temozolomide, and Hypofractionated Stereotactic Radiotherapy for Newly Diagnosed Glioblastoma. Clinical Cancer Research 2014, 20: 5023-5031. PMID: 25107913, PMCID: PMC4523080, DOI: 10.1158/1078-0432.ccr-14-0822.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBevacizumabBiopsyBrain NeoplasmsChemotherapy, AdjuvantCombined Modality TherapyDacarbazineFemaleGlioblastomaHumansMagnetic Resonance ImagingMaleMiddle AgedRadiosurgeryTemozolomideTreatment OutcomeYoung AdultConceptsObjective response rateOverall survivalRadiotherapy schedulesMedian overall survivalPhase II studyHypofractionated Stereotactic RadiotherapyPhase II trialApparent diffusion coefficient ratioRelative cerebral blood volumeDynamic susceptibility contrast perfusion MRICerebral blood volumeNeuropsychological test scoresMedian PFSPersistent hypermetabolismAdjuvant temozolomidePrimary endpointII studyII trialPoor OSStandard dosesFDG-PETPrognostic valuePoor prognosisHistorical controlsTumor volume
2012
Toxic erythema of chemotherapy following i.v. BU plus fludarabine for allogeneic PBSC transplant
Parker TL, Cooper DL, Seropian SE, Bolognia JL. Toxic erythema of chemotherapy following i.v. BU plus fludarabine for allogeneic PBSC transplant. Bone Marrow Transplantation 2012, 48: 646-650. PMID: 23165491, DOI: 10.1038/bmt.2012.218.Peer-Reviewed Original ResearchConceptsAllogeneic PBSC transplantCutaneous toxicityConditioning regimenPBSC transplantsToxic erythemaLow treatment-related mortalityDoses of BUEffective conditioning regimenPalms/solesTreatment-related mortalityEvaluable patientsMost patientsMedian onsetStandard dosesTransplant physiciansClinical presentationScrotal involvementSpecific therapyAllergic reactionsInappropriate treatmentRetrospective analysisHigh incidencePatientsMyeloid neoplasiaBU/
2010
Inducible activation of Cre recombinase in adult mice causes gastric epithelial atrophy, metaplasia, and regenerative changes in the absence of “floxed” alleles
Huh WJ, Mysorekar IU, Mills JC. Inducible activation of Cre recombinase in adult mice causes gastric epithelial atrophy, metaplasia, and regenerative changes in the absence of “floxed” alleles. AJP Gastrointestinal And Liver Physiology 2010, 299: g368-g380. PMID: 20413717, PMCID: PMC3774481, DOI: 10.1152/ajpgi.00021.2010.Peer-Reviewed Original ResearchConceptsInduction of CreGastric epithelial stem cellsSpasmolytic polypeptide-expressing metaplasiaFoci of hyperplasiaSubset of miceTdT-mediated dUTP nick end labelingRegenerative capacityDUTP nick end labelingNick end labelingStem cellsAntral polypsDNA damage markerChicken actin promoterEpithelial atrophyStandard dosesGastric bodyPositive apoptosisEpithelial stem cellsComplete healingProfound atrophyGastric mucosaDamage markersAdult miceLoxP-flanked allelesSevere injuries
2007
Artemether-lumefantrine versus amodiaquine plus sulfadoxine-pyrimethamine for uncomplicated falciparum malaria in Burkina Faso: a randomised non-inferiority trial
Zongo I, Dorsey G, Rouamba N, Tinto H, Dokomajilar C, Guiguemde R, Rosenthal P, Ouedraogo J. Artemether-lumefantrine versus amodiaquine plus sulfadoxine-pyrimethamine for uncomplicated falciparum malaria in Burkina Faso: a randomised non-inferiority trial. The Lancet 2007, 369: 491-498. PMID: 17292769, DOI: 10.1016/s0140-6736(07)60236-0.Peer-Reviewed Original ResearchConceptsUncomplicated falciparum malariaTreatment failureUncomplicated malariaArtemether-lumefantrineRecurrent parasitaemiaFalciparum malariaNew infectionsArtemisinin-based combination treatmentLate treatment failureEarly treatment failureNon-inferiority trialSymptomatic malariaEffective regimensPrimary endpointCombination regimensStandard dosesAvailable regimenCombination treatmentDrug susceptibilityPatientsAmodiaquineMalarial treatmentMalariaRegimensBobo-Dioulasso
2006
Interactions between Buprenorphine and Antiretrovirals. I. The Nonnucleoside Reverse-Transcriptase Inhibitors Efavirenz and Delavirdine
McCance-Katz EF, Moody DE, Morse GD, Friedland G, Pade P, Baker J, Alvanzo A, Smith P, Ogundele A, Jatlow P, Rainey PM. Interactions between Buprenorphine and Antiretrovirals. I. The Nonnucleoside Reverse-Transcriptase Inhibitors Efavirenz and Delavirdine. Clinical Infectious Diseases 2006, 43: s224-s234. PMID: 17109309, DOI: 10.1086/508187.Peer-Reviewed Original ResearchMeSH KeywordsAdultAlkynesArea Under CurveBenzoxazinesBuprenorphineCase-Control StudiesCohort StudiesCyclopropanesDelavirdineDose-Response Relationship, DrugDrug Administration ScheduleDrug InteractionsFemaleHIV InfectionsHumansMaleNarcotic AntagonistsOpioid-Related DisordersOxazinesProbabilityPrognosisReference ValuesReverse Transcriptase InhibitorsRisk AssessmentStatistics, NonparametricTreatment OutcomeConceptsNonnucleoside reverse transcriptase inhibitor efavirenzReverse transcriptase inhibitor efavirenzInhibitor efavirenzPharmacokinetics of buprenorphineOpiate withdrawal symptomsAdjustment of dosesEffects of buprenorphineHuman immunodeficiency virusConcentration-time curveOpioid-dependent participantsHealthy control participantsAntiretroviral administrationAdverse eventsAgonist medicationsHIV diseaseNegative volunteersStandard dosesOpioid dependenceImmunodeficiency virusBuprenorphine concentrationsWithdrawal symptomsAntiretroviral pharmacokineticsDrug interactionsOpiate dependenceBuprenorphine
2004
The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancer
Robert NJ, Vogel CL, Henderson IC, Sparano JA, Moore MR, Silverman P, Overmoyer BA, Shapiro CL, Park JW, Colbern GT, Winer EP, Gabizon AA. The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancer. Seminars In Oncology 2004, 31: 106-146. PMID: 15717740, DOI: 10.1053/j.seminoncol.2004.09.018.Peer-Reviewed Original ResearchConceptsConventional doxorubicinBreast cancerLiposomal anthracyclinesLiposomal doxorubicinHand-foot syndromeAdvanced breast cancerMultiple phase IIConventional anthracyclinesSystemic therapyProlong survivalStandard dosesContinuous infusionToxicity profileOptimal doseActive drugCytotoxic drugsHigh dosesIntermittent scheduleWeekly scheduleAnthracyclinesNormal tissuesTrastuzumabCancerDoxorubicinNauseaProton pump inhibitor co-therapy with nonsteroidal anti-inflammatory drugs--nice or necessary?
Laine L. Proton pump inhibitor co-therapy with nonsteroidal anti-inflammatory drugs--nice or necessary? Gastroenterological Disorders 2004, 4 Suppl 4: s33-41. PMID: 15580145.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsNonsteroidal anti-inflammatory drugsUpper GI symptomsNonselective nonsteroidal anti-inflammatory drugsLow-dose aspirinAnti-inflammatory drugsGI symptomsGI complicationsGI riskSide effectsDevelopment of NSAIDDaily proton pump inhibitor therapyHistamine-2 receptor antagonistsNSAID-induced gastric ulcersProton pump inhibitor therapyNSAID-induced ulcersGI side effectsUpper GI bleedingAnti-pyretic effectsGastrointestinal toxicityGI bleedingNSAID usersUlcer complicationsCardiovascular prophylaxisInhibitor therapyStandard doses
1996
The effect of gabapentin on brain gamma‐aminobutyric acid in patients with epilepsy
Petroff O, Rothman D, Behar K, Lamoureux D, Mattson R. The effect of gabapentin on brain gamma‐aminobutyric acid in patients with epilepsy. Annals Of Neurology 1996, 39: 95-99. PMID: 8572673, DOI: 10.1002/ana.410390114.Peer-Reviewed Original ResearchConceptsGamma-aminobutyric acidBrain GABA levelsGABA levelsHuman brain GABA levelsBrain gamma-aminobutyric acidHigh-dose gabapentinAntiepileptic drug treatmentEffect of gabapentinPartial epilepsy patientsTreatment of epilepsyMechanism of actionAdjunctive therapyStandard dosesDrug treatmentEpilepsy patientsOccipital cortexGabapentinPatientsClinical useEpilepsyHuman brainMagnetic resonanceTreatmentMagnetic resonance spectroscopyVivo measurements
1995
Gadoteridol-enhanced MR imaging of malignant hepatic tumors: effects of triple versus standard doses on lesion-liver contrast.
Petersein J, Saini S, Mitchell D, Davis P, Johnson C, Kuhlman J, Parisky Y, Runge V, Weinreb J, Bernardino M. Gadoteridol-enhanced MR imaging of malignant hepatic tumors: effects of triple versus standard doses on lesion-liver contrast. American Journal Of Roentgenology 1995, 165: 1157-61. PMID: 7572495, DOI: 10.2214/ajr.165.5.7572495.Peer-Reviewed Original ResearchConceptsLesion-liver CNRLesion-liver contrastStandard doseHepatic lesionsMR imagingMalignant hepatic tumorsMalignant liver lesionsMalignant hepatic massesAdministration of gadoteridolMalignant hepatic lesionsT1-weighted spin-echo imagingLiver MR imagingStandard dosesHepatic massHepatic tumorsTriple doseHigh doseMalignant lesionsLiver lesionsLesionsLiver SNRDoseTime pointsGradient-echo imagingLiver signal
1993
Effects of HIV infection on the serologic manifestations and response to treatment of syphilis in intravenous drug users.
Gourevitch M, Selwyn P, Davenny K, Buono D, Schoenbaum E, Klein R, Friedland G. Effects of HIV infection on the serologic manifestations and response to treatment of syphilis in intravenous drug users. Annals Of Internal Medicine 1993, 118: 350-5. PMID: 8094280, DOI: 10.7326/0003-4819-118-5-199303010-00005.Peer-Reviewed Original ResearchConceptsIntravenous drug usersTreatment of syphilisStages of syphilisSerologic manifestationsDrug usersNontreponemal titersHIV infectionHuman immunodeficiency virus (HIV) infectionMethadone maintenance treatment programHIV serologic statusHIV-seronegative patientsHIV-seropositive patientsImmunodeficiency virus infectionHIV seropositive casesMaintenance treatment programFulminant manifestationCD4 countCohort studyHIV-seropositiveClinical courseStandard dosesEarly syphilisClinical manifestationsSerologic statusSerologic tests
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply